AlloVir is developing off-the-shelf T-cell therapies against several common viruses, including flu and a type of herpes virus.
The new 3D model by the Allen Institute allows scientists to examine key cellular structures across mitosis stages together.
Novartis, Otsuka, Pfizer and Sanofi will use technology from Verily’s Project Baseline to carry out clinical studies in various disease areas.
Ocular Therapeutix’s drug-eluting tear duct plug for glaucoma fell just short of the primary endpoint of its first phase 3 trial.
The East Coast investor will primarily provide debt financing to enable companies to reach milestones with minimal equity dilution.
The deal will give Merck control of an experimental oral HIF-2α inhibitor that may challenge Keytruda for the metastatic renal cell carcinoma market.
Biotech-CRO hybrid Evotec is continuing its buying and collaborating strategy with its acquisition of U.S. biologics company Just Biotherapeutics.
Mount Sinai researchers showed that in male mouse models of heart attack, Cdx2 placental cells regenerated damaged tissue.
The Medicines Company announced long-term data for inclisiran, showing that the drug lowered “bad” LDL cholesterol by more than 50%.
Computing-enabled R&D shop Schrödinger will use its $110 million haul to advance its nascent pipeline of wholly owned drugs.